Genetic polymorphisms and immunologic profiles in arteriogenesis
Completed
- Conditions
- Obstructive coronary artery disease and collateral artery growth10011082
- Registration Number
- NL-OMON44569
- Lead Sponsor
- VU University Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 50
Inclusion Criteria
>18 years old
present chronic total occlusion of one of the coronaries
Patients who undergo succesfull PCI
Exclusion Criteria
-refusal or inabilty to give informed consent
-Age >80
-Immunologic disorder of disease, recent use of immunosuppressive drugs.
-haemodynamic unstablility
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Main study endpoints: the main study endpoints are collateral flow, as<br /><br>determined by CFI, arteriogenic polymorphism, determined by DNA-profile and<br /><br>immunologic phenotype. </p><br>
- Secondary Outcome Measures
Name Time Method <p>Heart function</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What genetic polymorphisms are associated with arteriogenesis in obstructive coronary artery disease patients in the GLACIER study?
How do immunologic profiles correlate with collateral artery growth in NL-OMON44569 observational trial?
What molecular mechanisms underlie arteriogenesis in coronary artery disease as studied by VU University Medical Center?
Are there specific biomarkers that predict successful collateral artery development in NL-OMON44569?
What therapeutic targets have emerged from genetic studies of arteriogenesis in coronary artery disease?